Contacting Audion, patients
Any personal information that is sent through the contact page will not be transferred to third parties, and will be kept securely by Audion with your consent only.
Patients contacting us because they are interested in participating in (future) clinical research at Audion will need to sign an informed consent form in order for us to keep your personal contact details and other information provided. If you contact us because you are interested in taking part in this study, please specify your country of residence.
This website contains information relating to health, diseases and treatments. This is for information purposes only and is not meant to be a substitute for the advice provided by your own doctor or healthcare professional. You should not use the information contained herein for diagnosing any illness or physical or mental issue. Audion will not respond to any such request, you should always consult your own doctor or healthcare professional.
This contact form can also be used to contact us to request information about what personal data is stored by us and for what purpose it is stored. In addition, you may have incorrect data corrected or data deleted that is inadmissible or no longer necessary to be stored even if you have given us consent to do so. We are at your disposal for information, wishes or suggestions on the subject of data protection.
Contacting Audion, partners and collaborators
Our lead drug development program is aimed at treating sensorineural hearing loss by regenerating lost inner ear hair cells. The goal of the drug development program is to obtain safety and clinical proof of concept data with a proprietary gamma-secretase inhibitor licensed from Eli-Lilly. The clinical study is done within an EU Horizon2020 funded consortium (REGAIN, http://www.regainyourhearing.eu). If you are interested in this program and partnering with Audion you are welcome to contact us through this page.
We are also interested in expanding and developing our IP portfolio with preclinical stage assets for the treatment of inner and middle ear diseases.If you are developing new treatments for inner and middle ear diseases and the programs are at the preclinical stage, please contact us to discuss a potential partnership.